Ozempic currently costs about $218 per month in Canada, but once generic drugs are on the scene, the price is expected to be ...

Roche and Zealand reason petrelintide could deliver weight loss comparable to glucagon-like peptide 1 (GLP-1) receptor ...

In the latest research, scientists from Canada tracked nearly 3,000 Americans who used either semaglutide, the active drug in ...

Vivani Medical will spin off Cortigent, its neurostimulation business, as an independently publicly traded company as it ...

Wealth host Brad Smith discusses some of Wednesday's trending stocks. Novo Nordisk (NVO) stock is sinking after European drugmaker Roche (ROG.SW) reached a deal with Zealand Pharma (ZEAL.CO) to ...

Harbour BioMed created Élancé Therapeutics to develop bispecific antibody drugs for weight loss. Elsewhere, Geron’s CEO is ...

Novo Nordisk’s semaglutide diabetes and weight loss drugs, Ozempic and Wegovy, are no longer officially in shortage in the US ...

President Donald Trump's nominee to lead the agency overseeing Medicare should divest financial ties to healthcare and ...

The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...

Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...

Roche is stepping into the hot weight-loss drug market currently dominated by Novo Nordisk (NVO) and Eli Lilly (LLY). The ...